Interesting thoughts Patient (and good to see there are still a few others interested in MLA!). I'm hoping that with the disposal of Medivet that the business will trade through successfully and not require a CR or SPP. I could however see them looking at a small acquisition of either a product or small device manufacturer - and proceeding with a small CR to fund this, in effect bolstering the bank balance by stealth. You're right though, the answer to that letter does leave the CR/SPP option open.
The revealing announcement (assuming no intra-quarter trading updates) will be the March quarterly issued end of April. This will be the first official clean quarter that doesn't include any Medivet costs/drag and should hopefully demonstrate what management have been saying all along that the company is trading well and cash flow positive. 56 days and counting!
With the SP @ 4.6c and a market cap of 6.5m, I'm seeing good value, and hoping we're at Rock bottom.
GLTA, DYOR, IMO etc....
MLA Price at posting:
4.6¢ Sentiment: Buy Disclosure: Held
